natgillin/translations-raw huggingface dataset:
Regulation as last amended by Regulation (EC) No 465/2005 (OJ L 77, 23.3.2005, p. 6 ).
Uredba, kakor je bila nazadnje spremenjena z Uredbo (ES) št. 465/2005 (UL L 77, 23.3.2005, str. 6).
OJ L 244, 29.9.2000, p. 27.
UL L 244, 29.9.2000, str. 27.
Clearance of the Paying Agencies' accounts — Financial year 2004
Potrditev obračunov plačilnih agencij – Finančno leto 2004
Amount to be recovered from or paid to the Member State
Znesek, ki ga je treba izterjati od države članice ali ji ga plačati
For the calculation of the amount to be recovered from or paid to the Member State the amount taken into account is, the total of the annual declaration for the expenditure cleared (col.a) or, the total of the monthly declarations for the expenditure disjoined (col.b).
Za izračun zneska, ki ga je treba izterjati od države članice ali ji ga plačati, se upošteva celotni letni obračun za potrjene izdatke (stol. a) ali celotni mesečni obračun za ločene izdatke (stol. b)
The reductions and suspensions are those taken into account in the advance system, to which are added in particular the corrections for the non-respect of payment deadlines established in August, September and October 2004.
Znižanja in opustitve so tista, ki se upoštevajo pri predplačilu, katerim so dodani zlasti popravki zaradi neupoštevanja plačilnih rokov, določenih v avgustu, septembru in oktobru 2004.
2004 — Expenditure for the Paying Agencies for which the accounts are
2004 – Izdatki za plačilne agencije, za katere so obračuni
Total a + b
Skupaj a + b
Reductions and suspensions for the whole financial year
Znižanja in opustitve za celo finančno leto
Total including reductions and suspensions
Skupni znesek z znižanji in opustitvami
Advances paid to the Member State for the financial year
Predplačila izvršena državi članici za finančno leto
Amount to be recovered from (–) or paid to (+) the Member State
Znesek, ki ga je treba izterjati od (–) države članice ali ji ga plačati (+)
cleared
potrjeni
disjoined
ločeni
= expenditure declared in the annual declaration
= izdatki, navedeni v letnih obračunih
= total of the expenditure in the monthly declarations
= celotni izdatki v mesečnih obračunih
Clearance of the Paying Agencies' accounts Financial year 2004
Potrditev obračunov plačilnih agencij – Finančno leto 2004
List of the Paying Agencies for which the accounts are disjoined and are subject of a later clearance decision
Seznam plačilnih agencij, za katere so obračuni ločeni in so predmet kasnejše potrditve
Paying Agency
Plačilna agencija
Annex I lists the amounts cleared by Member State.
Priloga I navaja zneske, ki jih je potrdila država članica.
The details of these amounts were described in the Summary Report that was presented to the Fund Committee at the same time as this Decision.
Podrobnosti o teh zneskih so bile opisane v zbirnem poročilu, ki je bilo predloženo Odboru za sklad istočasno kot ta odločba.
Council Decision 2005/387/JHA
Sklep Sveta 2005/387/PNZ
on the information exchange, risk-assessment and control of new psychoactive substances
o izmenjavi podatkov, oceni tveganja in nadzoru nad novimi psihoaktivnimi snovmi
Having regard to the Treaty on European Union, and in particular Articles 29, 31(1)(e) and 34 (2)(c) thereof,
ob upoštevanju Pogodbe o Evropski uniji in zlasti členov 29, 31(1)(e) in 34(2)(c) Pogodbe,
The particular dangers inherent in the development of psychoactive substances require rapid action by the Member States.
Posebne nevarnosti, ki izhajajo iz razvoja psihoaktivnih snovi, terjajo hitro ukrepanje držav članic.
When new psychoactive substances are not brought within the scope of criminal law in all Member States, problems may arise in cooperation between the judicial authorities and law enforcement agencies of Member States owing to the fact that the offence or offences in question are not punishable under the laws of both the requesting and the requested State.
Če nove psihoaktivne snovi niso podvržene kazenskemu pravu v vseh državah članicah, se zaradi dejstva, da enega ali več zadevnih kaznivih dejanj ni možno kaznovati po kazenskem pravu tako države prosilke kot tudi zaprošene države, lahko pojavijo težave pri sodelovanju med pravosodnimi organi in organi pregona držav članic.
The European Union Action Plan on Drugs 2000-2004 provided for the Commission to organise an appropriate assessment of the Joint Action of 16 June 1997 concerning the information exchange, risk assessment and the control of new synthetic drugs [2] (herineafter ‘the Joint Action’) taking into account the external evaluation commissioned by the European Monitoring Centre on Drugs and Drug Addiction (hereinafter ‘the EMCDDA’) of the early warning system.
Akcijski načrt Evropske unije na področju drog (2000–2004) od Komisije zahteva, da pripravi ustrezno oceno Skupnega ukrepa z dne 16. junija 1997 o izmenjavi podatkov, oceni tveganja in nadzoru novih sintetičnih drog [2] (v nadaljnjem besedilu „Skupni ukrep“) ob upoštevanju zunanje ocene sistema zgodnjega opozarjanja, ki jo je naročil Evropski center za spremljanje drog in zasvojenosti z drogami (v nadaljnjem besedilu „ECSDZD“).
The assessment showed that the Joint Action had fulfilled its expectations.
Ocena je pokazala, da je Skupni ukrep izpolnil pričakovanja.
Nevertheless, the outcome of the assessment made it clear that the Joint Action was in need of reinforcement and reorientation.
Kljub temu pa je iz rezultatov ocene razvidno, da je treba Skupni ukrep okrepiti in preusmeriti.
In particular, its main objective, the clarity of its procedures and definitions, the transparency of its operation, and the relevance of its scope had to be redefined.
Še posebej je treba na novo opredeliti njegov glavni cilj, jasnost njegovih postopkov in opredelitev, preglednost njegovega delovanja ter ustreznost področja njegove uporabe.
The Communication from the Commission to the European Parliament and the Council on the mid-term evaluation of the EU Action Plan on Drugs (2000-2004) indicated that changes to the legislation would be introduced in order to enhance action against synthetic drugs.
V sporočilu Komisije Evropskemu parlamentu in Svetu o vmesni oceni Akcijskega načrta EU na področju drog (2000–2004) je zapisano, da se bodo sprejele spremembe zakonodaje z namenom krepitve ukrepov proti sintetičnim drogam.
The mechanism as established by the Joint Action should therefore be adapted.
Mehanizem, kakršnega vzpostavlja Skupni ukrep, je zato treba prilagoditi.
New psychoactive substances can be harmful to health.
Nove psihoaktivne snovi lahko škodujejo zdravju.
The new psychoactive substances covered by this Decision may include medicinal products as defined in Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to veterinary medicinal products [3] and in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to medicinal products for human use [4].
Nove psihoaktivne snovi, na katere se nanaša ta sklep, lahko vsebujejo tudi zdravila, kot so opredeljena v Direktivi Evropskega parlamenta in Sveta 2001/82/ES z dne 6. novembra 2001 o zakoniku Skupnosti o zdravilih za uporabo v veterinarski medicini [3] in Direktivi Evropskega parlamenta in Sveta 2001/83/ES z dne 6. novembra 2001 o zakoniku Skupnosti o zdravilih za uporabo v humani medicini [4].
The information exchange under the early warning system, established under the Joint Action, has proved to be a valuable asset to the Member States.
Izmenjava podatkov v okviru sistema zgodnjega opozarjanja, ki ga je vzpostavil Skupni ukrep, se je izkazal kot dragocena pomoč državam članicam.
Nothing in this Decision should prevent Member States from exchanging information, within the European Information Network on Drugs and Drug Addiction (hereinafter ‘the Reitox network’), on emerging trends in new uses of existing psychoactive substances which may pose a potential risk to public health, as well as information on possible public health related measures, in accordance with the mandate and procedures of the EMCDDA.
Nič v tem sklepu ne sme preprečiti državam članicam, da v skladu s pooblastili in postopki ECSDZD v okviru Evropskega informacijskega omrežja za mamila in zasvojenost z mamili (v nadaljnjem besedilu „Reitox“) izmenjujejo podatke o nastajajočih trendih pri novih uporabah obstoječih psihoaktivnih snovi, ki lahko predstavljajo tveganje za javno zdravje, ter informacije o možnih zadevah, povezanih z javnim zdravjem.
No deterioration of either human or veterinary health care as a result of this Decision will be permitted.
Na podlagi tega sklepa ni dopustno nikakršno poslabšanje kakovosti zdravstvenega varstva ljudi ali živali.
Substances of established and acknowledged medical value are therefore excluded from control measures based on this Decision.
Zato so snovi, ki imajo dokazano in priznano zdravstveno vrednost, izključene iz nadzornih ukrepov na podlagi tega sklepa.
Suitable regulatory and public health related measures should be taken for substances of established and acknowledged medical value that are being misused.
V zvezi s snovmi z dokazano in priznano zdravstveno vrednostjo, ki se zlorabljajo, pa je treba sprejeti ustrezne ureditvene in javnozdravstvene ukrepe.
In addition to what is provided for under the pharmacovigilance systems as defined in Directive 2001/82/EC and in Directive 2001/83/EC, the exchange of information on abused or misused psychoactive substances needs to be reinforced and appropriate cooperation with the European Medicines Agency (hereinafter ‘EMEA’) ensured.
Poleg sistemov farmakovigilance, kot so opredeljeni v direktivah 2001/82/ES in 2001/83/ES, je treba okrepiti tudi izmenjavo podatkov o psihoaktivnih snoveh, ki se zlorabljajo ali protipravno uporabljajo, in zagotoviti ustrezno sodelovanje z Evropsko agencijo za vrednotenje zdravil (v nadaljnjem besedilu „EAVZ“).
The United Nations Commission on Narcotic Drugs (hereinafter ‘CND’) Resolution 46/7 ‘Measures to promote the exchange of information on new patterns of drug use and on psychoactive substances consumed’, provides a useful framework for action by the Member States.
Resolucija Komisije Združenih narodov za droge (v nadaljnjem besedilu „KZND“) št. 46/7 „Ukrepi za pospeševanje izmenjave podatkov o novih vzorcih uporabe drog in o uživanih psihoaktivnih snoveh“ predstavlja uporaben okvir za ukrepanje držav članic.
The introduction of deadlines into every phase of the procedure established by this Decision should guarantee that the instrument can react swiftly and enhances its ability to provide a quick-response mechanism.
Določitev rokov za vsako fazo postopka, ki ga določa ta sklep, naj bi zagotovila hitro odzivnost tega instrumenta in naj bi okrepila njegovo vlogo mehanizma za hitro odzivanje.
The Scientific Committee of the EMCDDA has a central role in the assessment of the risks associated with a new psychoactive substance, it will for the purpose of this Decision be extended to include experts from the Commission, Europol and the EMEA, and experts from scientific fields not represented, or not sufficiently represented, in the Scientific Committee of the EMCDDA.
Znanstveni odbor ECSDZD, ki ima osrednjo vlogo pri ocenjevanju tveganj v zvezi z novimi psihoaktivnimi snovmi, bo za potrebe tega sklepa razširjen s strokovnjaki iz Komisije, Europola in EAVZ ter s strokovnjaki s tistih znanstvenih področij, ki niso zastopana ali ki niso dovolj zastopana v ECSDZD.
The extended Scientific Committee that assesses the risks associated with new psychoactive substances should remain a concise technical body of experts, capable of assessing effectively all risks associated with a new psychoactive substance.
Razširjeni znanstveni odbor, ki ocenjuje tveganja v zvezi z novimi psihoaktivnimi snovmi, bi moral ostati relativno ozek tehnični organ strokovnjakov, sposobnih dejanskega ocenjevanja vseh tveganj v zvezi z novo psihoaktivno snovjo.
Therefore the extended Scientific Committee should be kept to a manageable size.
Velikost razširjenega znanstvenega odbora bi zato morala ostati obvladljiva.
Since the objectives of the proposed action, namely to bring about an exchange of information, a risk-assessment by a scientific committee and an EU-level procedure for bringing notified substances under control, cannot be sufficiently achieved by the Member States and can therefore, by reason of the effects of the envisaged action, be better achieved at European Union level, the Union may adopt measures, in accordance with the principle of subsidiarity as set out in Article 5 of the Treaty.
Ker cilja predlaganega ukrepa, in sicer izmenjave podatkov, ocene tveganja s strani znanstvenega odbora in postopka na ravni EU za uvedbo nadzora nad prijavljenimi snovmi, države članice ne morejo zadovoljivo doseči in ker ta cilj zaradi obsega in učinkov predlaganega ukrepa lažje doseže Evropska unija, Unija lahko sprejme ukrepe v skladu z načelom subsidiarnosti iz člena 5 Pogodbe ES.
In accordance with the principle of proportionality as set out in that Article, this Decision does not go what is beyond what is necessary in order to achieve those objectives
Skladno z načelom sorazmernosti iz navedenega člena ta sklep ne prekoračuje okvirov, ki so potrebni za doseganje navedenega cilja.
In conformity with Article 34(2)(c) of the Treaty, measures based upon this Decision can be taken by qualified majority as these measures are necessary to implement this Decision.
V skladu s členom 34(2)(c) Pogodbe se lahko ukrepi na podlagi tega sklepa sprejmejo s kvalificirano večino, saj so ti ukrepi nujni za njegovo izvajanje.
This Decision respects fundamental rights and observes the principles recognised by Article 6 of the Treaty and reflected in the Charter of Fundamental Rights of the European Union,
Ta sklep upošteva temeljne pravice in spoštuje načela, ki jih priznava člen 6 Pogodbe in odraža Listina o temeljnih pravicah Evropske unije –
This Decision establishes a mechanism for a rapid exchange of information on new psychoactive substances.
Ta sklep vzpostavlja mehanizem za hitro izmenjavo podatkov o novih psihoaktivnih snoveh.
It takes note of information on suspected adverse reactions to be reported under the pharmacovigilance system as established by Title IX of Directive 2001/83/EC.
Upošteva informacije o možnih škodljivih reakcijah, o katerih se poroča v okviru sistema farmakovigilance, ki ga vzpostavlja Naslov IX Direktive 2001/83/ES.
This Decision also provides for an assessment of the risks associated with these new psychoactive substances in order to permit the measures applicable in the Member States for control of narcotic and psychotropic substances to be applied also to new psychoactive substances.
Ta sklep predvideva tudi ocenjevanje tveganj v zvezi s temi novimi psihoaktivnimi snovmi, da bi se omogočila uporaba ukrepov nadzora nad narkotičnimi in psihotropnimi snovmi v državah članicah tudi za nove psihoaktivne snovi.
This Decision applies to substances not currently listed in any of the schedules to:
Ta sklep se uporablja za snovi, ki jih trenutno ni na seznamih iz:
the 1961 United Nations Single Convention on Narcotic Drugs, that may pose a comparable threat to public health as the substances listed in Schedule I or II or IV thereof, and
Enotne konvencije Združenih narodov o mamilih iz leta 1961 in ki lahko predstavljajo podobno nevarnost za javno zdravje kot snovi, naštete v seznamih I ali II ali IV te konvencije, ter
the 1971 United Nations Convention on Psychotropic Substances, that may pose a comparable threat to public health as the substances listed in Schedule I or II or III or IV thereof.
Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971 in ki lahko predstavljajo podobno nevarnost za javno zdravje kot snovi, naštete v seznamih I ali II ali III ali IV te konvencije.
This Decision relates to end-products, as distinct from precursors in respect of which Council Regulation (EEC) No 3677/90 of 13 December 1990 laying down measures to be taken to discourage the diversion of certain substances to the illicit manufacture of narcotic drugs and psychotropic substances [5], and Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors [6] provide for a Community regime.Article 3
Ta sklep se nanaša na končne proizvode za razliko od predhodnih sestavin, za katere ureditev v Skupnosti predvidevata Uredba Sveta (EGS) št. 3677/90 z dne 13. decembra 1990 o določitvi ukrepov, sprejetih za preprečevanje zlorabe nekaterih snovi za nezakonito proizvodnjo mamil in drugih psihotropnih snovi [5], ter Uredba Evropskega parlamenta in Sveta (ES) št. 273/2004 z dne 11. februarja 2004 o predhodnih sestavinah pri prepovedanih drogah [6].Člen 3
For the purpose of this Decision the following definitions shall apply:
V tem sklepu se uporabljajo naslednje opredelitve pojmov:
‘new psychoactive substance’ means a new narcotic drug or a new psychotropic drug in pure form or in a preparation;
„nova psihoaktivna snov“ pomeni narkotično drogo ali novo psihotropno drogo v čisti obliki ali v pripravku;
‘new narcotic drug’ means a substance in pure form or in a preparation, that has not been scheduled under the 1961 United Nations Single Convention on Narcotic Drugs, and that may pose a threat to public health comparable to the substances listed in Schedule I, II or IV;
„nova narkotična droga“ pomeni snov v čisti obliki ali v pripravku, ki je ni na seznamih Enotne konvencije Združenih narodov o mamilih iz leta 1961 in ki lahko predstavlja podobno nevarnost za javno zdravje kot snovi, naštete v seznamih I, II ali IV;
‘new psychotropic drug’ means a substance in pure form or in a preparation that has not been scheduled under the 1971 United Nations Convention on Psychotropic Substances, and that may pose a threat to public health comparable to the substances listed in Schedule I, II, III or IV;
„nova psihotropna droga“ pomeni snov v čisti obliki ali v pripravku, ki je ni na seznamih Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971 in ki lahko predstavlja podobno nevarnost za javno zdravje kot snovi, naštete v seznamih I, II, III ali IV;
‘marketing authorisation’ means a permission to place a medicinal product on the market, granted by the competent authority of a Member State, as required by Title III of Directive 2001/83/EC (in the case of medicinal products for human use) or Title III of Directive 2001/82/EC (in the case of veterinary medicinal products) or a marketing authorisation granted by the European Commission under Article 3 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency [7];
„dovoljenje za promet“ pomeni dovoljenje, da se zdravilo da na trg, ki ga izda pristojni organ države članice v skladu z naslovom III Direktive 2001/83/ES (če gre za zdravila za uporabo v humani medicini) ali z naslovom III Direktive 2001/82/ES (če gre za zdravila za uporabo v veterinarski medicini), ali dovoljenje za promet, ki ga izda Komisija v skladu s členom 3 Uredbe Evropskega parlamenta in Sveta (ES) št. 726/2004 z dne 31. marca 2004 o postopkih Skupnosti za pridobitev dovoljenja za promet in nadzor zdravil za humano in veterinarsko uporabo ter o ustanovitvi Evropske agencije za zdravila [7];
‘United Nations system’ means the World Health Organisation (WHO), the Commission on Narcotic Drugs (CND) and/or the Economic and Social Committee acting in accordance with their respective responsibilities as described in Article 3 of the 1961 United Nations Single Convention on Narcotic Drugs or in Article 2 of the 1971 United Nations Convention on Psychotropic Substances;
„sistem Združenih narodov“ pomeni Svetovno zdravstveno organizacijo (WHO), Komisijo za droge (CND) in/ali Ekonomsko-socialni odbor, ki delujejo vsak v skladu s svojimi pooblastili, kot so opisana v členu 3 Enotne konvencije Združenih narodov o mamilih iz leta 1961 in v členu 2 Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971;
‘preparation’ means a mixture containing a new psychoactive substance;
„pripravek“ pomeni mešanico, ki vsebuje „novo psihoaktivno snov“;
‘Reporting Form’ means a structured form for notification of a new psychoactive substance and/or of a preparation containing a new psychoactive substance agreed between the EMCDDA/Europol and their respective networks in the Member States’ Reitox and the Europol National Units.
„obrazec za poročanje“ pomeni strukturiran obrazec za prijavo nove psihoaktivne snovi in/ali pripravka, ki vsebuje novo psihoaktivno snov, o katerem so se dogovorili ECSDZD/Europol in njuni omrežji v državah članicah: Reitox in nacionalne enote Europola.
Each Member State shall ensure that its Europol National Unit and its representative in the Reitox network provide information on the manufacture, traffic and use, including supplementary information on possible medical use, of new psychoactive substances and of preparations containing new psychoactive substances, to Europol and the EMCDDA, taking into account the respective mandates of these two bodies.
Vsaka država članica zagotavlja, da njena nacionalna enota Europola in njen predstavnik v omrežju Reitox Europolu oz. ECSDZD, ob upoštevanju nalog teh dveh teles, posredujejo podatke o proizvodnji, prometu in uporabi novih psihoaktivnih snovi in pripravkov, ki vsebujejo nove psihoaktivne snovi, vključno z dodatnimi informacijami o njihovi možni uporabi v zdravstvene namene.
Europol and the EMCDDA shall collect the information received from Member States through a Reporting Form and communicate this information immediately to each other and to the Europol National Units and the representatives of the Reitox network of the Member States, the Commission, and to the EMEA.
Europol in ECSDZD zbirata podatke, ki jih prejmeta od držav članic, s pomočjo obrazca za poročanje in jih takoj posredujeta drug drugemu ter nacionalnim enotam Europola in predstavnikom omrežja Reitox v državah članicah, Komisiji in EAVZ.
Should Europol and the EMCDDA consider that the information provided by a Member State on a new psychoactive substance does not merit the communication of information as described in paragraph 1, they shall inform the notifying Member State immediately thereof.
Če Europol in ECSDZD ocenita, da podatka o novi psihoaktivni snovi, ki ga posreduje država članica, ni potrebno posredovati na način, opisan v odstavku 1, o tem takoj obvestita državo članico, ki je podatek posredovala.
Europol and the EMCDDA shall justify their decision to the Council within six weeks.
Europol in ECSDZD Svetu utemeljita svojo odločitev v roku šestih tednov.
Joint Report
Skupno poročilo
Where Europol and the EMCDDA, or the Council, acting by a majority of its members, consider that the information provided by the Member State on a new psychoactive substance merits the collection of further information, this information shall be collated and presented by Europol and the EMCDDA in the form of a Joint Report (hereinafter the ‘Joint Report’).
Če Europol in ECSDZD ali Svet z navadno večino oceni, da podatek o novi psihoaktivni snovi, ki ga posreduje država članica, zasluži nadaljnje zbiranje podatkov, Europol in ECSDZD te podatke zbereta in jih predstavita v obliki skupnega poročila (v nadaljnjem besedilu „skupno poročilo“).
The Joint Report shall be submitted to the Council, the EMEA and the Commission.
Skupno poročilo se predloži Svetu, EAVZ in Komisiji.
The Joint Report shall contain:
Skupno poročilo vsebuje:
a chemical and physical description, including the name under which the new psychoactive substance is known, including, if available, the scientific name (International Non-proprietary Name);
kemijski ali fizikalni opis, vključno z imenom, pod katerim je nova psihoaktivna snov poznana, in njenim znanstvenim imenom (kodo mednarodnega nelastniškega imena), če slednje obstaja;